Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 14Genitourinary 5Plasma cell 4Head & Neck 4Thoracic 3Other 3Lymphoid 3Gastrointestinal 3Other hematologic neoplasm 2Gynecologic 2Dermatologic 2Tumor-Agnostic 1Sarcoma 1Other solid neoplasm 1Myeloid 1Classical hematology 1CNS 1

Conditions

Neoplasms 1

Interventions

Paclitaxel 26Carboplatin 25pembrolizumab 22Gemcitabine 22Nivolumab 20Cisplatin 15Bevacizumab 14Docetaxel 13Pemetrexed 12Ipilimumab 12Erlotinib Hydrochloride 12Capecitabine 12Fluorouracil 11Irinotecan 10Afatinib 10eribulin 9BI 6727 9130-nm albumin-bound paclitaxel 9Radiotherapy 8Magnetic Resonance Spectroscopy 8Leucovorin 8Everolimus 8Cyclophosphamide 8Albumin-Bound Paclitaxel 8olaparib 7Oxaliplatin 7lenvatinib 6avelumab 6Trastuzumab 6Cetuximab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Sugars × Tumor-Agnostic × Clear all
NCT01238120 2021-05-05

The Effects of Physical Activity and Low-Dose Ibuprofen on Cognitive Function in Cancer Patients

University of Rochester

Phase 2 Completed
110 enrolled 15 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡